IGC Pharma, Inc. (IGC)

[NetworkNewsWire]

IGC Regains Listing Compliance

India Globalization Capital, Inc. (NYSE American: IGC), a developer of cannabis-based therapies to treat a variety of life-altering conditions, this morning announced that it has regained NYSE American listing compliance. The company received a letter on November 9, 2017, from NYSE Regulation stating that it is currently in compliance with the NYSE American LLC continued listing standards set forth in section 704 of the NYSE American Company Guide. This update came on the heels of IGC’s annual meeting, which took place on November 8, 2017. As noted in this morning’s news release, the company’s listing eligibility will continue to be assessed on an ongoing basis moving forward, as is the case for all listed issuers.

To view the full press release, visit http://nnw.fm/z926C

About IGC

IGC is engaged in the development of cannabis based combination therapies to treat Alzheimer’s, pain, nausea, eating disorders, several end points of Parkinson’s, and epilepsy in dogs and cats. IGC has assembled a portfolio of patent filings and four lead product candidates addressing these conditions. The company is based in Maryland, USA. For more information please visit www.igcinc.us